GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Price-to-Operating-Cash-Flow

Dianthus Therapeutics (Dianthus Therapeutics) Price-to-Operating-Cash-Flow : (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-06-05), Dianthus Therapeutics's share price is $21.74. Dianthus Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.38. Hence, Dianthus Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Dianthus Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

DNTH's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 25.785
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Dianthus Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.58. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.38.

Dianthus Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Dianthus Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Price-to-Operating-Cash-Flow Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
- - -

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of Dianthus Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Dianthus Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dianthus Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Price-to-Operating-Cash-Flow falls into.


Dianthus Therapeutics Price-to-Operating-Cash-Flow Calculation

Dianthus Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=21.74/-1.382
=

Dianthus Therapeutics's Share Price of today is $21.74.
Dianthus Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.38.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Dianthus Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Price-to-Operating-Cash-Flow
Comparable Companies
SELB INZY IKNA MACK CBUS PSTX ALVR STOK TCRX ATXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
87E:Germany
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Website
https://www.dianthustx.com
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023